Ironwood Pharmaceuticals Inc

Healthcare · Drug Manufacturers - Specialty & Generic

3.60$ -3.2% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Income Statement

Ironwood Pharmaceuticals Inc (IRWD) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 113 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement IRWD
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	66	87	52	65	87	94	69	81	66	131	69	102	131	126	80	89	103	117	89	104	104	117	98	97	109	107	104	107	114	118	75	94	92	91	41	85	122	48	107	113	389
Cost of Revenue	38	1.9	0.5	3.5	6.1	9.1	2.6	4.1	4.6	21	1.0	11	0.5	11	2.2	0.6	22	0.9	15	12	11	0.4	11	0.4	0.4	0.3	0.3	20	0.5	0.5	26	0.5	30	78	27	0.5	0.5	0.5	0.4	–	–
Gross Profit	29	86	52	62	81	85	67	77	61	109	68	91	131	115	78	89	82	116	73	92	93	117	87	97	108	107	104	88	113	118	49	94	62	91	14	85	122	48	106	113	388
Research & Development	38	38	34	37	37	40	37	39	47	44	54	29	28	27	28	21	22	16	18	12	11	31	11	11	11	10	13	1,125	32	36	26	30	30	25	27	23	22	22	21	22	88
Selling, General & Administrative	45	55	56	58	62	58	62	68	55	58	65	43	41	39	36	35	35	34	28	27	28	29	29	30	29	28	31	52	36	39	38	37	36	34	24	17	22	19	12	11	65
Total Operating Expenses	86	90	90	96	101	102	102	111	103	102	119	72	68	66	64	56	36	64	28	27	28	60	29	41	40	38	44	1,171	65	80	38	69	36	59	43	40	44	41	34	34	152
Operating Income	-28	-6.3	-40	-41	-19	23	-36	-40	-169	6.0	-54	22	66	50	13	33	46	51	45	65	65	57	58	56	68	68	60	-1,083	49	38	11	25	26	31	-29	45	78	6.6	73	79	236
Interest Expense	9.8	9.7	9.0	9.0	9.1	9.2	9.3	9.4	9.5	9.6	9.6	9.4	10	7.1	7.2	7.3	7.4	7.5	7.6	7.7	7.8	8.0	2.3	2.2	1.5	1.5	1.5	1.8	9.8	8.4	7.2	7.5	9.4	8.9	8.1	8.4	8.4	7.9	9.1	7.2	33
Pre-Tax Income	-33	-14	-53	-44	-32	12	-43	-49	-174	-15	-59	12	21	48	3.3	25	36	45	40	54	60	46	56	54	70	72	66	-1,076	32	30	5.0	19	17	24	-36	38	68	0.5	65	74	207
Income Tax Expense	9.5	9.3	9.0	9.0	9.1	8.6	8.6	8.7	9.5	7.5	9.6	9.6	11	6.6	6.9	7.0	1.4	1.3	0.4	-337	3.8	4.9	18	17	20	23	20	13	18	32	9.1	20	14	22	1.1	14	28	2.7	24	22	78
Net Income	-33	-14	-53	-44	-32	12	-43	-49	-174	-15	-59	12	21	48	3.3	25	34	43	40	391	56	41	39	37	50	49	46	-1,062	15	-1.1	-4.2	-0.9	3.6	2.3	-37	24	40	-2.3	41	51	130
EBITDA	-18	-4.4	-40	-33	-20	27	-29	-7.4	-162	-4.6	-12	23	34	56	11	33	49	54	46	65	65	55	59	56	72	74	68	56	42	41	12	27	27	33	-10	47	77	8.8	75	81	241

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings